Most children with JPsA show improved disease activity over the first 2 years of treatment, despite requiring early systemic therapy.
Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...
Patients with D2T-PsA can be stratified into inflammatory and noninflammatory phenotypes, with the former linked to higher sonographic activity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback